Table of Contents
Thrombosis
Volume 2012 (2012), Article ID 184573, 8 pages
http://dx.doi.org/10.1155/2012/184573
Review Article

Anticoagulant and Antiplatelet Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease

1Department of Cardiology, Pneumology, Angiology and Intensive Care Medicine, University Hospital, RWTH Aachen University, 52072 Aachen, Germany
2Department of Cardiology, Maastricht University Hospital, 6202 AZ Maastricht, The Netherlands

Received 9 November 2011; Accepted 2 February 2012

Academic Editor: Louis M. Aledort

Copyright © 2012 Karl Mischke et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. J. Camm, P. Kirchhof, G. Y. H. Lip et al., “Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC),” European Heart Journal, vol. 31, no. 19, pp. 2369–2429, 2010. View at Google Scholar
  2. R. G. Hart, O. Benavente, R. McBride, and L. A. Pearce, “Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis,” Annals of Internal Medicine, vol. 131, no. 7, pp. 492–501, 1999. View at Google Scholar · View at Scopus
  3. M. Nabauer, A. Gerth, T. Limbourg et al., “The registry of the German competence NETwork on atrial fibrillation: patient characteristics and initial management,” Europace, vol. 11, no. 4, pp. 423–434, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Nieuwlaat, A. Capucci, A. J. Camm et al., “Atrial fibrillation management: a prospective survey in ESC Member Countries: the Euro Heart Survey on atrial fibrillation,” European Heart Journal, vol. 26, no. 22, pp. 2422–2434, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. D. J. Gladstone, E. Bui, J. Fang et al., “Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated,” Stroke, vol. 40, no. 1, pp. 235–240, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. S. Paikin, D. S. Wright, M. A. Crowther, S. R. Mehta, and J. W. Eikelboom, “Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents,” Circulation, vol. 121, no. 18, pp. 2067–2070, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Sørensen, M. L. Hansen, S. Z. Abildstrom et al., “Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data,” The Lancet, vol. 374, no. 9706, pp. 1967–1974, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. J. B. Olesen, G. Y. H. Lip, J. Lindhardsen et al., “Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a “real world” nationwide cohort study,” Thrombosis and Haemostasis, vol. 106, no. 4, pp. 739–749, 2011. View at Publisher · View at Google Scholar
  9. E. L. Grove and R. F. Storey, “The right oral antithrombotics in acute coronary syndromes,” The Lancet, vol. 374, no. 9706, pp. 1947–1948, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Dewilde and J. T. Berg, “Design and rationale of the WOEST trial: what is the optimal antiplatelet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST),” American Heart Journal, vol. 158, no. 5, pp. 713–718, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Y. H. Lip, K. Huber, F. Andreotti et al., “Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary. A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI),” European Heart Journal, vol. 31, no. 11, pp. 1311–1318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Daemen, P. Wenaweser, K. Tsuchida et al., “Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study,” Lancet, vol. 369, no. 9562, pp. 667–678, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Mischke and R. Hoffmann, “ESC guidelines on atrial fibrillation: impact on management of patients after stentimplantation,” European Heart Journal, vol. 31, no. 19, pp. 2369–2429, 2010. View at Publisher · View at Google Scholar
  14. R. C. Becker, T. W. Meade, P. B. Berger et al., “The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition),” Chest, vol. 133, no. 6, supplement, pp. 776S–814S, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Van De Werf, J. Bax, A. Betriu et al., “Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation,” European Heart Journal, vol. 29, no. 23, pp. 2909–2945, 2008. View at Publisher · View at Google Scholar
  16. E. L. Eisenstein, K. J. Anstrom, D. F. Kong et al., “Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation,” Journal of the American Medical Association, vol. 297, no. 2, pp. 159–168, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. H. C. Gwon, J. Y. Hahn, W. Park et al., “Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of Xience/Promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study,” Circulation, vol. 125, no. 3, pp. 505–513, 2012. View at Google Scholar
  18. M. Valgimigli, G. Campo, G. Percoco et al., “Randomized comparison of 6-versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention: design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY),” American Heart Journal, vol. 160, no. 5, pp. 804–811, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. J. Connolly, J. Pogue, R. G. Hart et al., “Effect of clopidogrel added to aspirin in patients with atrial fibrillation,” New England Journal of Medicine, vol. 360, no. 20, pp. 2066–2078, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. L. S. Wann, A. B. Curtis, C. T. January et al., “2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American college of cardiology foundation/American heart association task force on practice guidelines,” Circulation, vol. 123, no. 1, pp. 104–123, 2011. View at Publisher · View at Google Scholar
  21. S. Connolly, J. Pogue, R. Hart et al., “Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial,” Lancet, vol. 367, no. 9526, pp. 1903–1912, 2006. View at Google Scholar
  22. S. J. Connolly, M. D. Ezekowitz, S. Yusuf et al., “Dabigatran versus warfarin in patients with atrial fibrillation,” New England Journal of Medicine, vol. 361, no. 12, pp. 1139–1151, 2009. View at Publisher · View at Google Scholar
  23. C. B. Granger, J. H. Alexander, J. J.V. McMurray et al., “Apixaban versus warfarin in patients with atrial fibrillation,” New England Journal of Medicine, vol. 365, no. 11, pp. 981–992, 2011. View at Publisher · View at Google Scholar
  24. S. J. Connolly, J. Eikelboom, C. Joyner et al., “Apixaban in patients with atrial fibrillation,” New England Journal of Medicine, vol. 364, no. 9, pp. 806–817, 2011. View at Publisher · View at Google Scholar
  25. M. R. Patel, K. W. Mahaffey, J. Garg et al., “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation,” New England Journal of Medicine, vol. 365, no. 10, pp. 883–891, 2011. View at Publisher · View at Google Scholar
  26. J. W. Eikelboom, L. Wallentin, S. J. Connolly et al., “Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial,” Circulation, vol. 123, no. 21, pp. 2363–2372, 2011. View at Publisher · View at Google Scholar
  27. J. L. Mega, E. Braunwald, S. D. Wiviott et al., “Rivaroxaban in patients with a recent acute coronary syndrome,” New England Journal of Medicine, vol. 366, no. 1, pp. 9–19, 2012. View at Publisher · View at Google Scholar
  28. M. L. Hansen, R. Sørensen, M. T. Clausen et al., “Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation,” Archives of Internal Medicine, vol. 170, no. 16, pp. 1433–1441, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. A. L. Dans, S. Connolly, M. Brückmann et al., “Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial,” in Proceedings of the ESC Congress, Paris, France, 2011.
  30. M. L. O'Donoghue, D. L. Bhatt, S. D. Wiviott et al., “Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial,” Circulation, vol. 123, no. 17, pp. 1843–1853, 2011. View at Publisher · View at Google Scholar
  31. D. A. Morrow, B. M. Scirica, K. A. A. Fox et al., “Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial,” American Heart Journal, vol. 158, no. 3, pp. 335–341, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. D. Wiviott, M. D. Flather, M. L. O'Donoghue et al., “Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial,” Circulation, vol. 123, no. 17, pp. 1854–1863, 2011. View at Publisher · View at Google Scholar
  33. P. G. Steg, K. Huber, F. Andreotti et al., “Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology,” European Heart Journal, vol. 32, no. 15, pp. 1854–1864, 2011. View at Publisher · View at Google Scholar
  34. S. S. Jolly, S. Yusuf, J. Cairns et al., “Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial,” The Lancet, vol. 377, no. 9775, pp. 1409–1420, 2011. View at Publisher · View at Google Scholar
  35. G. W. Stone, B. Witzenbichler, G. Guagliumi et al., “Bivalirudin during primary PCI in acute myocardial infarction,” New England Journal of Medicine, vol. 358, no. 21, pp. 2218–2230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. N. S. Abraham, M. A. Hlatky, E. M. Antman et al., “ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,” Circulation, vol. 122, no. 24, pp. 2619–2633, 2010. View at Publisher · View at Google Scholar · View at Scopus